"The U.S. is an important market for MedMira and building out our distribution network is a key initiative in maintaining and expanding our market position. Adding VWR to our U.S. distribution network will increase our sales revenues and enable us to fully capitalize on opportunities to launch new products in the market," said
"We provide our customers with the most innovative products available on the market today. Adding MedMira's 3-minute rapid HIV test to our product portfolio will provide our U.S. customers with a critical diagnostic tool," said
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
SOURCE MEDMIRA INC.